Targeting scleral remodeling and myopia development in form deprivation myopia through inhibition of EFEMP1 expression

Biochim Biophys Acta Mol Basis Dis. 2024 Mar;1870(3):166981. doi: 10.1016/j.bbadis.2023.166981. Epub 2023 Dec 14.

Abstract

The role of extracellular matrix (ECM) remodeling in the axial elongation associated with myopia has not been fully elucidated, although it is considered a significant factor. EFEMP1, a regulator of ECM, has been associated with various pathological conditions. This study aimed to examine the involvement of EFEMP1 in scleral remodeling during form deprivation myopia. The results indicate a progressive increase in EFEMP1 expression following prolonged form deprivation treatment, followed by a subsequent decrease upon recovery. To gain a deeper understanding of the mechanism of EFEMP1, we conducted transcriptome sequencing on primary scleral fibroblasts that were subjected to lentivirus-mediated overexpression of EFEMP1. Validation was performed using lentivirus-induced overexpression and shRNA targeting EFEMP1 in combination with LY294002, a PI3K inhibitor. Our findings suggest that EFEMP1 may be involved in the development of FDM by regulating the expression of the PI3K/AKT/MMP2 axis. The AAV-mediated injection of shEFEMP1 under Tenon's capsule in guinea pigs was observed to effectively delay the progression of myopia and posterior scleral remodeling. In contrast, the AAV-mediated overexpression of EFEMP1 exacerbated the development of myopia and resulted in further thinning of collagen fibers in the posterior sclera. In summary, adjusting EFEMP1 concentrations could potentially serve as a viable approach to prevent and treat myopia by influencing the remodeling process of the posterior sclera.

Keywords: EFEMP1; Fibroblast; Form deprivation myopia; MMP2; Scleral remodeling.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Extracellular Matrix / metabolism
  • Fibroblasts / metabolism
  • Guinea Pigs
  • Myopia* / genetics
  • Myopia* / metabolism
  • Myopia* / therapy
  • Phosphatidylinositol 3-Kinases / metabolism
  • Sclera* / metabolism
  • Sclera* / pathology

Substances

  • Phosphatidylinositol 3-Kinases